Odyssey Therapeutics, Inc. (ODTX) vs Rigel Pharmaceuticals, Inc. (RIGL)
A side-by-side comparison of Odyssey Therapeutics, Inc. and Rigel Pharmaceuticals, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
ODTX
Odyssey Therapeutics, Inc.
$18.34HealthcareDelayed quote: Oct 6, 2026, 2:43 PM EDT
RIGL
Rigel Pharmaceuticals, Inc.
$46.65HealthcareDelayed quote: Oct 6, 2026, 2:45 PM EDT
Total return — ODTX vs RIGL
growth of $100 · dividends reinvested · last 1yODTX +26.9% (+26.9%/yr)RIGL +62.6% (+62.6%/yr)RIGL compounded faster over this window
ODTX RIGL
ODTX vs RIGL: by the numbers
- •ODTX is the larger company ($881M vs $863M market cap).
- •RIGL is profitable (116.30% net margin) while ODTX runs a net loss (-4994.86%).
Metrics side by side
Valuation
| Metric | ODTX | RIGL |
|---|---|---|
| P/E ratio | N/A | 2.86 |
| Forward P/E | N/A | 13.60 |
| P/S ratio | N/A | 3.12 |
| P/B ratio | 2.09 | 2.03 |
| EV / EBITDA | N/A | 9.39 |
| FCF yield | N/A | 9.20% |
Profitability
| Metric | ODTX | RIGL |
|---|---|---|
| Gross margin | 100.00% | 91.39% |
| Operating margin | -5415.19% | 42.63% |
| Net margin | -4994.86% | 116.30% |
| ROE | N/A | 75.67% |
| ROIC | -66.23% | 18.72% |
Growth (annualized)
| Metric | ODTX | RIGL |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 13.94% |
| Total return CAGR (5Y) | N/A | 6.25% |
Frequently asked
- Is ODTX or RIGL more profitable?
- RIGL runs the higher net margin — ODTX at -4994.86% versus RIGL at 116.30%.
Go deeper
Dig into the metrics
Rigel Pharmaceuticals P/E ratioOdyssey Therapeutics ROERigel Pharmaceuticals ROEOdyssey Therapeutics operating marginRigel Pharmaceuticals operating marginOdyssey Therapeutics revenue growthRigel Pharmaceuticals revenue growthOdyssey Therapeutics free cash flowRigel Pharmaceuticals free cash flow
Odyssey Therapeutics & Rigel Pharmaceuticals appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.